Nintedanib Al

Nintedanib, the active ingredient in Nintedanib Al, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and selected non‑small cell lung cancer. The drug blocks several growth‑factor receptors that drive fibroblast activity and abnormal vascular formation, slowing disease progression. It meets EU pharmaceutical standards and is prescribed by pulmonology and oncology specialists.

GNH USA supplies Nintedanib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is used in fibrotic lung disorders and certain oncologic settings, targeting pathways that promote fibroblast proliferation and tumor angiogenesis.

- Idiopathic pulmonary fibrosis: slows decline in lung function, reduces forced vital capacity loss, and may improve quality of life. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory status in affected patients. - Non‑small cell lung cancer: used in combination regimens to inhibit tumour growth and angiogenesis, contributing to disease control.

Nintedanib may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often manageable with diet and antidiarrheal agents. - Nausea: mild to moderate feeling of queasiness. - Vomiting: occasional episodes. - Elevated liver enzymes: increases in ALT/AST observed in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring and possible discontinuation. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Gastrointestinal perforation: rare but serious intestinal ulceration.

When prescribing Nintedanib, clinicians should observe several safety considerations to minimise risk.

- Liver function monitoring: check ALT/AST before treatment and periodically during therapy. - Bleeding risk assessment: avoid use in patients with active bleeding or on strong anticoagulants. - Gastrointestinal health: monitor for severe diarrhea or ulceration, especially in patients with prior GI disease. - Cardiovascular evaluation: assess history of arterial thrombotic events before initiating therapy. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Nintedanib exposure, raising toxicity risk. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): combined use can enhance bleeding tendency.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma levels. - P‑glycoprotein substrates (e.g., digoxin): potential for altered absorption. - Antacids containing aluminium or magnesium: may reduce oral bioavailability if taken simultaneously.